ReposiTrak (TRAK) Q4 2024 earnings summary

Executive summary

• Achieved record recurring revenue, net income, and EPS growth in fiscal 2024, with the highest cash balance in company history.

• Full-year revenue grew 7% to $20.5 million, with recurring revenue also up 7% to $20.4 million, reflecting strong SaaS platform performance and traceability network expansion.

• Net income to common shareholders increased 8% year-over-year to $5.4 million, with basic EPS rising 11% to $0.30.

• Returned over $5.6 million to shareholders via dividends, buybacks, and preferred share redemptions.

• Rebranded, uplisted to NYSE, and established the Traceability Network as a market leader.

Financial highlights

• Q4 revenue up 8% year-over-year to $5.2 million; recurring revenue nearly 100% of total.

• Q4 GAAP net income up 15% to $1.6 million; EPS $0.08 vs. $0.07 last year.

• FY24 revenue up 7%; recurring revenue 99% of total; GAAP net income up 7% to $5.9 million.

• FY24 EPS $0.30 basic, $0.29 diluted, up from $0.27 last year.

• Record cash balance of $25.2 million at year-end, with no bank debt.

Outlook and guidance

• Traceability expected to double annual recurring revenue run rates over three years at 80%+ margins.

• Revenue growth expected to accelerate as traceability network on-boarding gains momentum.

• Traceability revenue contribution to increase sequentially in FY25, accelerating toward the FDA’s January 2026 deadline.

• Pipeline of new hubs and suppliers expected to drive significant ARR growth quarter by quarter.